Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
And now it's going red. I still agree with you but weird. Many mj stocks in same boat.
I agree. But regarding sell off on Level 2 this morning, it's been routine now for a drop in price after announcing good quarterly results...
Traders getting out. Just like the other mj stocks of late.
Thank you.
Revenue is one thing but a billion in revenue, what about Profits?
Is MRMD really a profitable company?
Are they reporting on Thursday?
LCK: Almost every mj stock is in the crapper lately. Even Tru who reported good numbers continues to sink. MRMD reported outstanding numbers last night. Most think it will continue to move down even though they now have a clean balance sheet.
Even Jushi who Ranger Pete says will be $15 by the end of 2021. What's your take? Sector rotation? Goblin shorts?
We'll see you in a week, then.
This happens all the time. If you look at other mj stocks, they are all down on little volume - like Trulieve and of course GTI is down because they didn't follow protocol. Ooooooo.
We all have our stories. Zzzzz
Nice to see you iggy!
Okay, you want a bigger bang? Get in your time machine and come with me... I bought Cresco like twenty months ago when everybody hated all mj stocks. Cresco had bought Origin and between the two, I had about 4000 shares. Cresco was like $2.38 then, so for me, it's not 36%.
Where were you, then?
Dr. Lalezari also wrote to Janet Woodcock
Subject: Leronlimab for critical Covid
Date: March 10, 2021 at 3:32:08 PM PST
To: "Janet.Woodcock"
Dear Dr. Woodcock,
The FDA has protected the American public during Covid by issuing various EUAs, but no treatment has been advanced that specifically helps our most vulnerable citizens-those who are critically ill. And unfortunately, with variant strains now circulating, a potential 4th wave is possible.
CytoDyn’s CD12 trial is the first randomized, double-blind, placebo-controlled study to suggest a striking survival benefit for critically ill Covid patients (24% reduced mortality; p value nss). The study demonstrates statistical significance on a variety of crucial secondary endpoints including shortened hospital stay (6 days; P=0.005), improved survival in patients who received SOC therapy (N=309; P=0.031), and improved survival in patients under 65 years of age, including both all patients under 65 (N=221; P=0.02) and well as those who were critically ill (N=44; P=0.006). The study also demonstrated no safety concerns, consistent with the benign safety profile seen in about 1,000 other HIV+, cancer, and Covid patients who have received leronlimab. The unfortunate imbalance in randomization of patients > 65 years of age (and especially > 75 years) in the CD12 study should not, however, prevent patient access to a potentially life saving medication now while a study of additional critically ill patients is underway. Taken together, the CD12 efficacy signals in critically ill patients combined with the consistently benign safety profile, provide a compelling risk:benefit ratio and ample justification for FDA to issue an EUA for leronlimab for this population now.
I am consulting in the care of a 57 year old man with critical Covid who was on ECMO for 61 days at St. Thomas hospital in London. He received emergency leronlimab on day 79 of his hospitalization and starting weaning off ECMO 4 days later. I have attached the case report below, which has been peer reviewed and accepted for publication. Please give it your consideration. Though anecdotal, this case underscores the dramatic recovery that is possible with leronlimab even in the most critically ill patients with Covid.
I have been an independent investigator on about 50 POC studies of novel antiviral agents over the last 31 years (including HIV, CMV, HCV, HBV, HSV, HPV, and Influenza). Also, I have no equity stake in this.
I know leronlimab to be safe and I believe it can help save critically ill patients with Covid-19.
Please give these patients and their medical teams a fighting chance.
Respectfully,
Jacob Lalezari, MD
Director, Quest Research
SF, CA
Does Indiva only make edibles?
Do you own High Times?
Probably a good idea. Good thinking.
Kind of confusing post.
What do you mean buckle up. A good thing or bad?
Okay but no one touches GE Jim's statement - isn't there truth in that:
"I hear you, but at the end of the day, they still lost money. In fact more than what was projected. Not much on the smoke and mirror stuff, just show me the money, the earnings, the FCF, the rest is all for show."
Most cannabis right now is a crap shoot!
Let them sell. I’ll buy their shares. Know what you own. “Be Happy!”
I hate to inform you but you are eternal optimist. Par for the course, just like Leronlimab.
Good, we all agree. Don’t know why you are in a hurry to sell all your Cresco shares...
Thank you!
No reason to dilute unless they're buying something. Iggy is right.
At this point, it's just a game.
You must be mistaken. It's Verano!
What do you mean it's not TV?
If you buy a Samsung - the company now offers web channels for free - provided that you have internet service. Apple TV is a streaming device that comes through a TV - the lines of broadcast is very blurred but nonetheless, it's streaming TV.
https://www.samsung.com/us/televisions-home-theater/tvs/tvplus/
Well, I was wrong.
It turns out that the broadcast aired on Yahoo Finance website on February 17.
The video is 6:30 minutes long and at about 4:40 mark that chart showing the multiples of several hydrogen companies appear.
It's an interesting video because PTAP is building out the U.S. hydrogen fueling station infrastructure.
https://finance.yahoo.com/video/powertap-raghu-kilambi-explains-why-152021003.html
I said it was a broadcast on Yahoo Finance web channel. There is no *** link. It is NOT a website.
What don't you understand?
This was a broadcast on Yahoo Finance web channel, not website. There was no mention of fossil fuel companies. The PTAP CEO was talking strictly about the imminent and impending arrival of hydrogen - gave examples like Texas - that from a cost advantage, hydrogen was much cheaper to implement now than a few years ago.
Okay, so when I thought further about the PTAP interview, the list was not in alphabetical order. FCEL was at the top of the list because its multiple was the highest at 15x. Others like Ballard, Plug and others, their multiple was lower.
The overall interview was positive. The PTAP CEO was saying that hydrogen was the next fuel and no denying it any longer.
So this evening I was flipping through web channels and came upon an interview by the CEO of Power Tap. He was saying that hydrogen fuel cells and fuel cell cars will be a ready technology within two years. Then they posted a screen of the important fuel cell companies, showing multiples. FCEL was at the top, might have been alphabetical and it showed that FCEL was 15x. Almost all of the companies were less than 15x. The broadcast was on Yahoo Finance.
BWA: Black-Ops has posted numerous times NEVER to use stop loss. Ever - especially for this stock.
Ever!
Thank you. I wish the best for this company!
With NP’s preponderance for shouting any news from every media outlet, think about it, HH. We are in an unprecedented time and plans must be in place or you are talking catastrophic news instead of glorious news. Someone bigger has ordered NP to keep mum on the news. We already know that LL is BIG.
Whataboutdat!
I was trying to be positive toward another poster on this board that Liberty was doing well.